江苏诺泰澳赛诺生物制药股份有限公司_公司详情_供应商

制药在线首页

公司概况
成立年份： 2004
总资产(USD)： 100,000,000至249,999,999
员工总人数： 500以上
主要竞争优势：品牌，国际认证/标准，经验丰富的研发人员，发货速度，生产能力，产品线丰富，合同定制，接受买家的规格要求，接受小额订单，良好的信誉，优质服务
其他竞争优势： CDMO PEPTIDE API PEPTIDE CDMO 多肽专家,国内最大的原料生产供应商。 FDA, NMPA cGMP Sinopep is specialized in the development and the manufacturing via solid phase peptide synthsis and liquid phase peptide synthesis. From technical aspect, we have expertise technology of peptide products both in LPPS and SPPS field. We can adopt the LPPS and SPPS strategoes together for manufacturing peptide products. Such as , Liraglutide and semaglutide projects: We synthesize main chain through SPPS strategy; meanwhile, we obtain side chain and segments via LPPS. From manufacturing aspect, providing CDMO service from research scale(gram-scale batch) to bulk cGMP Active Pharmaceutical Ingredient (API)(kg-scale batch-10kg-scale batch) . The manufacturing capability of Sinopep is biggest in China at this time. From regulatory aspect, Sinopep has a strong regulatory background and we are well prepared to fully support you required regulatory documentation such as DMF and technical package. Eptifibatide and bivalirudin DP from our end users are commercialized in EU and US market. Thymalfasin and Octreotide are commercial in China market.
专利与版权：

业务概况
业务类型：制造商，出口商
年销售额(USD)： 500,000,000至749,999,999
主要销售市场：北美洲，中/南美洲，西欧，东欧，大洋洲，亚洲，中东，非洲
主要产品类别：原料药，中间体，生物制品，合同外包、定制服务及咨询
所有产品： Sinopep is specialized in the development and the manufacturing via solid phase peptide synthsis and liquid phase peptide synthesis. From technical aspect, we have expertise technology of peptide products both in LPPS and SPPS field. We can adopt the LPPS and SPPS strategoes together for manufacturing peptide products. Such as , Liraglutide and semaglutide projects: We synthesize main chain through SPPS strategy; meanwhile, we obtain side chain and segments via LPPS. From manufacturing aspect, providing CDMO service from research scale(gram-scale batch) to bulk cGMP Active Pharmaceutical Ingredient (API)(kg-scale batch-10kg-scale batch) . The manufacturing capability of Sinopep is biggest in China at this time. From regulatory aspect, Sinopep has a strong regulatory background and we are well prepared to fully support you required regulatory documentation such as DMF and technical package. Eptifibatide and bivalirudin DP from our end users are commercialized in EU and US market. Thymalfasin and Octreotide are commercial in China market.
外销比重：
内销比重：
主要客户：

其它信息
合同定制： CRO,CMO
付款条款：

公司详情

江苏诺泰制药有限公司是集研发、生产、销售和技术服务为一体的高新技术企业，成立于2009年4月，总投资4.5亿元。公司目前已建有研发中心和多个符合cGMP标准的生产车间，下一步将建设片剂、胶囊剂、颗粒剂、冻干粉针剂和注射剂等多个符合FDA标准的制剂车间，使公司形成以蛋白质多肽类药物为主，化学药物为辅，兼具多品种原料药和制剂生产能力的生物医药企业。公司主要业务涵盖了创新药物开发、研发外包服务（客户肽定制）、生物制品和活**物成分（APIs）的生产等，目标市场包括欧美等国外市场。依据国际设计理念建设的研发中心，建筑面积3500平方米，包括质量检测中心、研发实验室和中试车间等。优秀的人才队伍和强大的研发实力为企业的发展提供了智力支持和能力保障，严格的质量管理和先进的生产技术构成了企业发展的基础。诺泰制药确立了创新和国际化两大发展战略，我们正努力将公司建设成为国内、国际知名、具有核心竞争力的创新型高科技生物医药企业。

Sinopep is specialized in the development and the manufacturing via solid phase peptide synthsis and liquid phase peptide synthesis.
From technical aspect, we have expertise technology of peptide products both in LPPS and SPPS field.
We can adopt the LPPS and SPPS strategoes together for manufacturing peptide products. Such as , Liraglutide and semaglutide projects: We synthesize main chain through SPPS strategy; meanwhile, we obtain side chain and segments via LPPS.
From manufacturing aspect, providing CDMO service from research scale(gram-scale batch) to bulk cGMP Active Pharmaceutical Ingredient (API)(kg-scale batch-10kg-scale batch) . The manufacturing capability of Sinopep is biggest in China at this time.
From regulatory aspect, Sinopep has a strong regulatory background and we are well prepared to fully support you required regulatory documentation such as DMF and technical package. Eptifibatide and bivalirudin DP from our end users are commercialized in EU and US market. Thymalfasin and Octreotide are commercial in China market.

联系我们